Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

Katrina S. Pedersen, Patrick M. Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang, Andrea Wang-Gillam, Benjamin Tan

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry